

The trajectory of high sensitivity C-reactive protein is associated with incident diabetes in Chinese adults

Ren-ying Xu (✉ xurenying7465@126.com)

Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital <https://orcid.org/0000-0003-2608-5586>

Xiaomin Jiang

Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital

Zhuping Fan

Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital

Yanping Wan

Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital

Xiang Gao

Pennsylvania State University University Park : Penn State

Research

Keywords: trajectory, high sensitivity C-reactive protein (hs-CRP), diabetes

Posted Date: June 18th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-17400/v2>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published on June 30th, 2020. See the published version at <https://doi.org/10.1186/s12986-020-00472-w>.

Abstract

Background: We performed a cohort study to evaluate the association between the CRP trajectory and incident diabetes in Chinese adults.

Methods: Included were 6,439 adults (4,111 men and 2,249 women; aged 46.6 ± 11.9 years). The concentration of high sensitivity CRP (hs-CRP) was measured in 2013 (baseline), 2014, and 2015. The hs-CRP trajectory was identified based the above three measurements by latent mixture modeling. Incident diabetes cases were diagnosed by fasting blood glucose (≥ 126 mg/dl) or Hb A1c ($\geq 6.5\%$) during subsequent three years (2016-2018).

Results: Hs-CRP concentration during 2013 -2015 was classified into 3 levels: low (<1.0 mg/L), moderate (1.0–3.0 mg/L), and high (≥ 3.0 mg/L) based on a statement by American Heart Association. We named four hs-CRP trajectories as following: “low-stable” (low in 2013 and maintained at low concentration in 2014 and 2015), “moderate-fluctuated” (moderate in 2013, then increased to high concentration in 2014, and decreased to low concentration in 2015), “high-decreased” (high in 2013 but decreased to moderate concentration in 2014 and 2015), and “moderate-increased (moderate in 2013 and increased to high concentration in 2014 and 2015)”. We identified 235 incident diabetes during subsequent three years. The adjusted HR for incident diabetes was 1.71 (95% CI: 1.02, 2.87) comparing the moderate-increased and the low-stable group, after adjusting for potential confounders. In the secondary analyses, two single-measured hs-CRP concentration (in 2013 or in 2015) and the average of hs-CRP were associated with high risk of diabetes (P-trend <0.01 for all).

Conclusions: The hs-CRP trajectory pattern was associated with altered incident diabetes in Chinese adults.

Background

It is estimated that people with diabetes will reach an alarming number of 366 million in 2030 globally (1). Diabetes causes a series of microvascular and macrovascular changes (2), thus leads the increased prevalence of disability and mortality and throws a heavy burden to human health.

One of the most important strategies to curb the dramatic increase of diabetes is to identify people with high risk for diabetes and to implement early intervention. C-reactive protein (CRP), a classical inflammatory biomarker, has been considered as an indicative parameter for diabetes and related complications in both cross-sectional (3-5) and longitudinal studies (6-10). However, almost all the above-mentioned studies focused on baseline measure of CRP and neglected long-term change. The concentration of CRP changes in life (11). Not taken time-varying and cumulative average over time into consideration might may lead to misclassification of CRP status and result in confuses (12). For example, one clinical trial suggested that CRP may not be an optimal factor to predictive changes in cardiovascular risk among diabetic patients (13) while another cohort study did not find the association between baseline CRP and incident diabetes over thirteen-year follow up (14).

Based on repeated variable, trajectory analysis taking its advantage over traditional analysis lies in its unique ability to record long-term change over time. Thus, the trajectory approach could account for the dynamic natural change overtime and facilitate to identify a cluster of individuals who have similar longitudinal change patterns of CRP (15, 16). Therefore, the aim of this study was to prospectively evaluate the association between the CRP trajectory during 2013-2015 and subsequent risk of diabetes, as assessed by both fasting blood glucose (FBG) and glycated hemoglobin A1c (HbA1c), in approximately 6,300 Chinese adults. As secondary analyses, we also examined the association between baseline (2013), and cumulative average of high sensitivity CRP (hs-CRP) and future diabetes risk.

Methods

Study population

All the participants were recruited from Health Management Center from January 1, 2013 to October 31, 2018. A total number of 55,155 adults with measurements of FBG, HbA1c and hs-CRP was eligible for the study. The concentration of hs-CRP was measured at 2013 (baseline), 2014, and 2015 and the trajectory was identified based on the three measurements. HbA1c and FBG were repeatedly annually measured during five years of follow up. We excluded participants with history of diabetes, high HbA1c ($\geq 6.5\%$), high fasting blood glucose (≥ 7.0 mmol/L) or extremely high concentration of hs-CRP (≥ 10 mg/L) during 2013-2015, and those lost to follow up. Because hs-CRP status is strongly influenced by presence of cardiovascular disease, cancer and major metabolic disorders (hypertension, dyslipidemia and hyperuricemia), we further excluded participants with these conditions. Finally, included were 6,349 adults (4,111 men and 2,238 women; 18-89 years old) in the analysis (**Supplemental Figure 1**). Participants included in the study were younger, with higher proportion of women, and lower concentration of hs-CRP, FBG, and HbA1c at baseline, compared with those were not included (**Supplemental Table 1**). The study protocol was approved by the Ethical Committee of Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University. As a de-identified secondary data analysis, patients' consent was waived by the Ethical Committee.

2.2 Assessment of incident diabetes

Venous blood samples were drawn and transfused into vacuum tubes containing EDTA in the morning after participants were fasted for six hours. The whole blood was stored at 4°C for further analysis. The level of HbA1c was measured by high performance liquid chromatography, using the fully automated VARIANT™ II Hemoglobin Testing System (Bio-Rad, U.S). The measurement range was between 2.0% and 18.0%. An automatic analyzer (Roche 701 Bioanalyzer, Roche, UK) was used to measure FBG with the hexokinase/glucose-6-phosphate dehydrogenase method. The coefficient of variation using blind quality control specimens was 2.0%. Diabetes was confirmed if FBG (≥ 7.0 mmol/L=126mg/dl) or HbA1c ($\geq 6.5\%$) (17, 18).

Measurement of hs-CRP and other biochemical parameters

The concentration of hs-CRP was measured by immunotubidimetric method (CardioPhase hsCRP kit, Siemens Healthcare Diagnostics Products GmbH, German). The lower limit of detection was 0.01 mg/L. The intraassay CV was 7.6% and the interassay CV was 4.0%. Hs-CRP concentration during 2013 -2015 was classified into 3 categories: low (<1.0 mg/L), moderate (1.0–3.0 mg/L), and high (\geq 3.0 mg/L) based on a statement by American Heart Association (19).

The following variables were measured at baseline. Total cholesterol, triglycerides, high-density-lipoprotein cholesterol, low-density-lipoprotein cholesterol, and blood creatinine were measured by enzyme linked immunosorbent assay (Roche 701 Bioanalyzer, Roche, UK). White blood cell (WBC) were also measured. All the measurements were completed in the Clinical Laboratory of Ren Ji Hospital. The eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration 2-level race equation (20).

Assessment of other confounders

Body weight and height were annually measured, and BMI was calculated by body weight (kg) divided by height square (m²). The latest BMI was calculated as the latest BMI measured before the onset of the diabetes (e.g., if incident diabetes was determined in 2016, then BMI measured in 2015 was used). Blood pressure and history of the diseases were obtained at baseline. **Blood pressure was measured twice using an automatic blood-pressure meter (HBP-9020, OMRON (China) Co., Ltd.) after participants were seated for at least 10 min. The average of two measurements was recorded for further analysis. The history of hypertension, diabetes/impaired fasting glucose, dyslipidemia, hyperuricemia, stroke and hemorrhage, and coronary heart diseases (coronary atherosclerosis, coronary artery bypass grafting, stent surgery, and ischemic infarction) collected via a self-report questionnaire** if the participants were diagnosed with these diseases by a physician or they were taking any drugs for these diseases (21).

Statistical analysis

Data were presented as mean \pm standard deviation. Since hs-CRP was in abnormal distribution, it was square transformed. We completed all statistical analyses by SAS version 9.4 (SAS Institute, Inc, Cary, NC). The correlation between FBG, HbA1c, BMI, blood pressure, lipid profile, and eGFR was evaluated by Spearman correlation analysis. Formal hypothesis testing will be two-sided with a significant level of 0.05. The person-time of follow-up for each participant was determined from January 1, 2016 to either the onset date of diabetes, or the end of follow-up (December 31, 2018), whichever came first. The time unit for the analysis was a month.

The hs-CRP trajectory was identified by **PROC TRAJ** procedure based on three measurement obtained in 2013, 2014, and 2015 (12, 22). A basic one group model was fitted with all groups set to a quadratic equation. Then, we fitted a two-group, three-group, three-group, four-group, and five-group model as well. The model with four groups was identified as the best, as suggested by the lowest value of Bayesian

information criterion. We then compared the model with different functional forms. In the final model, we had one pattern with a quadratic order term and three patterns with a cubic order term. Further, we calculated the posterior predicted probability for each participant of being a member of each trajectory (15). The average posterior probability for each trajectory was 0.84, 0.87, 0.85, and 0.83.

In secondary analyses, we used baseline hs-CRP, hs-CRP in 2015, and the average of three measurements of CRP as exposures. Participants were further classified into following groups based on either single assessment of hs-CRP in 2013, in 2015, or the average of hs-CRP during 2013-2015: low-risk (<1.0 mg/L), intermediate-risk (1.0–3.0 mg/L), and high-risk (\geq 3.0 mg/L) (19).

We used the proportional hazards Cox model to evaluate the association between the hs-CRP trajectory and incident diabetes. We adjusted for potential confounders in two different models: **model 1**, adjusting for age (y) and sex; and **model 2** further adjusting baseline BMI (kg/m²), systolic blood pressure (mmHg), diastolic blood pressure (mmHg), total cholesterol (mmol/L), triglycerides (mmol/L), low-density-lipoprotein cholesterol (mmol/L), high-density-lipoprotein cholesterol (mmol/L), eGFR (ml/min/1.73m²), FBG (mmol/L), and HbA1c (%) because these variables were closely associated with both FBG and HbA1c (**Supplemental Table 2**). In a secondary analysis, we further adjusted for hs-CRP (2013) to understand whether the potential association between hs-CRP trajectory and diabetes risk was driven by the baseline CRP status, although we were aware of the risk of over-adjustment and collinearity.

We tested the interaction between hs-CRP trajectory and sex, age (<65y vs. \geq 65y) (12), and BMI (<28.0 vs. \geq 28.0 kg/m²) (23), in relation to incident diabetes.

Results

In the current study, mean baseline age, square-transformed hs-CRP, and HbA1c was 46.6 \pm 11.9 years, 0.93 \pm 0.48 mg/L, and 5.4 \pm 0.3%, respectively. Baseline characteristics were presented in **Table 1**.

We identified four hs-CRP trajectories in the study population: 77.4% (n=5,174) of the participants whose baseline hs-CRP concentration was low and maintained stable (referred as “low-stable”), 14.2% (n=679) of the participants whose baseline hs-CRP was moderate but changed dramatically (referred as “moderate-fluctuated”), 5.0% (n=288) of the participants whose baseline hs-CRP were high but decreased to moderate concentration (referred as “high-decreased”), and 3.4% (n=208) of the participants whose baseline hs-CRP was moderate and increased to high concentration (referred as “moderate-increased”) (**Figure 1**). The average concentration of hs-CRP in 2013, 2014, and 2015 was presented in **Supplemental Table 3**.

We identified 235 incident diabetes over subsequent three years after 2015. Each standard deviation (\approx 1.02 mg/L) of cumulative hs-CRP during follow up (2016-2018) was associated with 24% (HR=1.24, 95% CI: 1.04, 1.47) higher risk of developing diabetes in multivariate-adjusted model. Compared with the low-stable group, moderate-increased group was associated with the highest likelihood of incident diabetes (HR=1.71, 95% CI: 1.02, 2.87) (**Table 2**). Further adjusting for baseline hs-CRP (**Table 2**) did not

materially change the association. Similar significant results were observed when we further adjusted for baseline WBC (adjusted HR comparing the two groups was 1.69, 95%CI: 1.002, 2.84). Including the latest BMI in multivariate-adjusted model got similar results with main analysis (**Supplemental Table 4**).

We did not find the association between high-decreased and moderate-fluctuated trajectories, and risk of incident diabetes. Both baseline and the cumulative average hs-CRP were associated with high risk of incident diabetes (**Table 3**). We did not find the significant interaction between sex, age, and BMI, in relation to incident diabetes (P-interaction >0.1 for all).

Discussion

In the current study, we observed four hs-CRP trajectories and found that the “moderate-increased” trajectory was associated with subsequent risk of diabetes in about 6,300 Chinese adults free of cardiovascular disease, cancer and major metabolic disorders at baseline, after adjusting for potential confounders. Consistent with previous studies (4, 7), we found that both baseline and the average of hs-CRP were associated with incident diabetes. Our results strengthen the concept that inflammation is involved in the etiology of developing diabetes (24).

Hs-CRP has been reported to be associated with both cardiovascular diseases and diabetes in previous studies (25-27). However, it may not be optimal to evaluate baseline hs-CRP and incident diabetes because baseline hs-CRP could not reflect longitudinal changes in inflammation status. Data were limited to evaluate the association between changes in hs-CRP and incident diabetes. Tabák *et al.* (11) reported that CRP concentrations increased with time among both incident diabetes cases and controls in a cohort study in 7,350 British participants. However, they did not evaluate the association between changes in CRP and the risk of incident diabetes. Another cohort study included 14,228 participants without diabetes and followed them for thirteen years. The concentration of hs-CRP was repeatedly measured. Changes in CRP were found to be associated with increase in HbA1c by linear mix model, but the association between each standard deviation increase in CRP was not associated with annual changes in HbA1c ($p=0.15$) (28). Another observational study included 42 patients with type 1 and 94 patients with type 2 diabetes. Two-year changes (2-year follow-up divided by baseline) of CRP was associated with two-year increases of HbA1c (29). Our study found that individuals with increased hs-CRP concentration during 2013-2015 (i.e., the moderate-increased trajectory) had ~70% higher subsequent diabetes risk, relative to those with stably low hs-CRP concentration over 2 years. The association did not materially change after we further adjusted for baseline hs-CRP concentration, suggesting longitudinal change in hs-CRP could be important for diabetes risk. Similar to our study, Parrinello *et al.* (30) classified participants into four different groups based on two hs-CRP measurements. Compared to persons with sustained low/moderate hs-CRP ($\leq 3\text{mg/L}$), those with increased or sustained high hs-CRP ($>3\text{mg/L}$) had an increased risk of incident diabetes, whereas those with decreased hs-CRP did not. However, it might be

less stable to calculate the trajectory by using two measurements. Further, we found that the high-decreased trajectory was not associated with the risk of incident diabetes.

Strengths of the present study included a large sample size of healthy Chinese adults free of hypertension, diabetes, dyslipidemia, coronary heart diseases, hyperuricemia, stroke, and cancer at baseline. To the best of our knowledge, this is the first study describing the association between the trajectory of hs-CRP and incident diabetes. Four analytical approaches including baseline, the measurement in 2015, cumulative average, and trajectories were analyzed to strengthen the reliability of the results.

Our study has several limitations. First, we did not collect information about history of autoimmune diseases such as inflammatory bowel diseases, systemic lupus erythematosus, celiac disease, glomerulonephritis, and asthma. The diseases themselves could increase the concentration of hs-CRP and its drugs used in these diseases might also increase the concentration of blood glucose as well. However, the incidence of these diseases in general population is low in China (31-35) and the dosage of corticosteroid during the quiescent phase of the diseases is low. We thus assumed the possible impacts of the diseases and its related treatment is minimal in the current study. Further, smoking, diet, and physical activity were not collected and may lead to residual confounding. Although we collected the information on smoking, the self-report prevalence of smoking was very low (1%) compared with about 30% of the current smokers in Chinese adults (36). We thus did not include smoking variable in the model. Second, information regarding acute inflammation and infection was not collected in the current study. We could not exclude the possibility that high hs-CRP was caused by acute inflammation (26), rather than low-grade systemic inflammation. However, we excluded participants with hs-CRP ≥ 10 mg/L in the analyses. Further adjusting WBC also did not change the association. Then, we did not collect information about diabetes mellitus-related medications, which were reported to be associated with hs-CRP (37, 38). However, we excluded patients whose FBG ≥ 7.0 mmol/L or HbA1c $\geq 6.5\%$ at baseline, which might mitigate the distraction because these participants were most likely to receive such treatment. Information on metabolic diseases was self-reported and we cannot exclude the possibility of recall bias, thus some participants with metabolic diseases might remain in the study. Further, incident diabetes was identified by FBG and postprandial hyperglycemia was not taken into consideration, which might result in underdiagnosis of diabetes cases. However, it is acceptable to identify diabetes cases by FBG in some of epidemiological studies (14, 39). Third, we did not review medical records and the onset of the diseases was assessed at the visit time. However, the FBG and HbA1c examination has been conducted every year. Diabetes confirmed by single measurement of FBG or HbA1c, but had not further been assessed by oral glucose tolerance test, might lead to misclassification of diabetes status. Fourth, we did not consider seasonal fluctuations in FBG and HbA1c (40, 41), and thus we could not exclude the possibility of misdiagnosis of incident cases of diabetes. Finally, study population was recruited from Healthy Examination in our hospital, which could not represent of general population. Prospective studies with representative population, and deliberately collection of information about potential confounders, and long follow up are warranted to confirm our results in the future.

Conclusion

The moderate-increased trajectory of hs-CRP was associated with incident diabetes in Chinese adults.

Abbreviations

CRP, C-reactive protein

eGFR, estimated glomerular filtration rate

FBG, fasting blood glucose

HbA1c, Glycated hemoglobin A1c

Hs-CRP, high sensitivity C-reactive protein

Declarations

Ethical approval: The study was approved by the Ethics Committee of Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University. As a de-identified secondary data analysis, patients' consent was waived by the Ethical Committee.

Consent for publication: All authors have read and approved the submission of the manuscript. The manuscript has not been published and is not being considered for publication elsewhere, in whole or in part, in any language.

Availability of database: All the datasets and SAS code are available upon readers' request.

Competing interests: No potential conflicts of interest relevant to this article were reported.

Author contribution: Xu R.Y. designed the study, analyzed the data and drafted the paper; Jiang X.M., Fan Z.P., and Wan Y.P. collected the data and completed part of the data analysis; Gao X approved the final paper.

Funding: The study was supported by the grants from Pu Dong Medical Bureau (PW2016D-05), and by the grant from Shanghai Key Laboratory of Pediatric Gastroenterology and Nutrition (No.17DZ2272000).

Acknowledgements Thanking for Dr An-hu Li (School of Mechanical Engineering, Tongji University, Shanghai 201804, China) for drawing the picture.

References

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes Care*. 2004;27(5):1047-53.
2. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ*. 2000;321(7258):405-12.
3. Seo SM, Baek SH, Jeon HK, Kang SM, Kim DS, Kim WS, et al. Correlations between the level of high-sensitivity C-reactive protein and cardiovascular risk factors in Korean adults with cardiovascular disease or diabetes mellitus: the CALLISTO study. *J Atheroscler Thromb*. 2013;20(7):616-22.
4. Mazidi M, Toth PP, Banach M. C-reactive Protein Is Associated With Prevalence of the Metabolic Syndrome, Hypertension, and Diabetes Mellitus in US Adults. *Angiology*. 2018;69(5):438-42.
5. Zhao Y, Wang R, Ma X, Yan X, Zhang Z, He X, et al. Distribution of C-reactive protein and its association with cardiovascular risk factors in a population-based sample of Chinese. *Dis Markers*. 2010;28(6):333-42.
6. Hwang YC, Morrow DA, Cannon CP, Liu Y, Bergenstal R, Heller S, et al. High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial. *Diabetes Obes Metab*. 2018;20(3):654-9.
7. Koloverou E, Panagiotakos DB, Georgousopoulou EN, Chrysohoou C, Tousoulis D, Stefanadis C, et al. Single and combined effects of inflammatory markers on 10 year diabetes incidence: The mediating role of adiposity-Results from the ATTICA cohort study. *Diabetes Metab Res Rev*. 2018;34(1).
8. Cardoso CR, Leite NC, Salles GF. Prognostic Importance of C-Reactive Protein in High Cardiovascular Risk Patients With Type 2 Diabetes Mellitus: The Rio de Janeiro Type 2 Diabetes Cohort Study. *J Am Heart Assoc*. 2016;5(11).
9. Mc Causland FR, Claggett B, Burdmann EA, Eckardt KU, Kewalramani R, Levey AS, et al. C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). *Am J Kidney Dis*. 2016;68(6):873-81.
10. Muni RH, Kohly RP, Lee EQ, Manson JE, Semba RD, Schaumberg DA. Prospective study of inflammatory biomarkers and risk of diabetic retinopathy in the diabetes control and complications trial. *JAMA Ophthalmol*. 2013;131(4):514-21.
11. Tabak AG, Kivimaki M, Brunner EJ, Lowe GD, Jokela M, Akbaraly TN, et al. Changes in C-reactive protein levels before type 2 diabetes and cardiovascular death: the Whitehall II study. *Eur J Endocrinol*. 2010;163(1):89-95.
12. Jin C, Chen S, Vaidya A, Wu Y, Wu Z, Hu FB, et al. Longitudinal Change in Fasting Blood Glucose and Myocardial Infarction Risk in a Population Without Diabetes. *Diabetes Care*. 2017;40(11):1565-72.
13. Khatana SA, Taveira TH, Choudhary G, Eaton CB, Wu WC. Change in hemoglobin A(1c) and C-reactive protein levels in patients with diabetes mellitus. *J Cardiometab Syndr*. 2009;4(2):76-80.
14. Julia C, Czernichow S, Charnaux N, Ahluwalia N, Andreeva V, Touvier M, et al. Relationships between adipokines, biomarkers of endothelial function and inflammation and risk of type 2 diabetes.

- Diabetes Res Clin Pract. 2014;105(2):231-8.
15. Song M, Hu FB, Wu K, Must A, Chan AT, Willett WC, et al. Trajectory of body shape in early and middle life and all cause and cause specific mortality: results from two prospective US cohort studies. *BMJ*. 2016;353:i2195.
 16. Franklin JM, Shrank WH, Pakes J, Sanfelix-Gimeno G, Matlin OS, Brennan TA, et al. Group-based trajectory models: a new approach to classifying and predicting long-term medication adherence. *Med Care*. 2013;51(9):789-96.
 17. American Diabetes A. (2) Classification and diagnosis of diabetes. *Diabetes Care*. 2015;38 Suppl:S8-S16.
 18. American Diabetes A. Diagnosis and classification of diabetes mellitus. *Diabetes Care*. 2014;37 Suppl 1:S81-90.
 19. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, 3rd, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. *Circulation*. 2003;107(3):499-511.
 20. Kong X, Ma Y, Chen J, Luo Q, Yu X, Li Y, et al. Evaluation of the Chronic Kidney Disease Epidemiology Collaboration equation for estimating glomerular filtration rate in the Chinese population. *Nephrol Dial Transplant*. 2013;28(3):641-51.
 21. Wang YL, Koh WP, Yuan JM, Pan A. Plasma ferritin, C-reactive protein, and risk of incident type 2 diabetes in Singapore Chinese men and women. *Diabetes Res Clin Pract*. 2017;128:109-18.
 22. Jones BL, Nagin, D.S. Advances in group-based trajectory modeling and an SAS procedure for estimating them. *Sociol Methods Res*. 2007;35:542-71.
 23. Consultation WHOE. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. *Lancet*. 2004;363(9403):157-63.
 24. Lontchi-Yimagou E, Sobngwi E, Matsha TE, Kengne AP. Diabetes mellitus and inflammation. *Curr Diab Rep*. 2013;13(3):435-44.
 25. Xu R, Zhang Y, Gao X, Wan Y, Fan Z. High-Sensitivity CRP (C-Reactive Protein) Is Associated With Incident Carotid Artery Plaque in Chinese Aged Adults. *Stroke*. 2019;50(7):1655-60.
 26. Wu Z, Huang Z, Jin W, Rimm EB, Lichtenstein AH, Kris-Etherton PM, et al. Peripheral Inflammatory Biomarkers for Myocardial Infarction Risk: A Prospective Community-Based Study. *Clin Chem*. 2017;63(3):663-72.
 27. Meng YX, Ford ES, Li C, Quarshie A, Al-Mahmoud AM, Giles W, et al. Association of C-reactive protein with surrogate measures of insulin resistance among nondiabetic US from National Health and Nutrition Examination Survey 1999-2002. *Clin Chem*. 2007;53(12):2152-9.
 28. Ahmadi-Abhari S, Kaptoge S, Luben RN, Wareham NJ, Khaw KT. Longitudinal association of C-reactive protein and Haemoglobin A1c over 13 years: the European Prospective Investigation into Cancer–Norfolk study. *Cardiovasc Diabetol*. 2015;14:61.

29. Weber KS, Nowotny B, Strassburger K, Pacini G, Mussig K, Szendroedi J, et al. The Role of Markers of Low-Grade Inflammation for the Early Time Course of Glycemic Control, Glucose Disappearance Rate, and beta-Cell Function in Recently Diagnosed Type 1 and Type 2 Diabetes. *Diabetes Care*. 2015;38(9):1758-67.
30. Parrinello CM, Lutsey PL, Ballantyne CM, Folsom AR, Pankow JS, Selvin E. Six-year change in high-sensitivity C-reactive protein and risk of diabetes, cardiovascular disease, and mortality. *Am Heart J*. 2015;170(2):380-9.
31. Zhou YQ, Xu RY, Wan YP. The role of dietary factors in inflammatory bowel diseases: New perspectives. *J Dig Dis*. 2019;20(1):11-7.
32. Rees F, Doherty M, Grainge MJ, Lanyon P, Zhang W. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. *Rheumatology (Oxford)*. 2017;56(11):1945-61.
33. Yang Y, Zhang Z, Zhuo L, Chen DP, Li WG. The Spectrum of Biopsy-Proven Glomerular Disease in China: A Systematic Review. *Chin Med J (Engl)*. 2018;131(6):731-5.
34. Singh P, Arora A, Strand TA, Leffler DA, Catassi C, Green PH, et al. Global Prevalence of Celiac Disease: Systematic Review and Meta-analysis. *Clin Gastroenterol Hepatol*. 2018;16(6):823-36 e2.
35. Lin J, Wang W, Chen P, Zhou X, Wan H, Yin K, et al. Prevalence and risk factors of asthma in mainland China: The CARE study. *Respir Med*. 2018;137:48-54.
36. Wang M, Luo X, Xu S, Liu W, Ding F, Zhang X, et al. Trends in smoking prevalence and implication for chronic diseases in China: serial national cross-sectional surveys from 2003 to 2013. *Lancet Respir Med*. 2019;7(1):35-45.
37. Liu Y, Jiang X, Chen X. Liraglutide and Metformin alone or combined therapy for type 2 diabetes patients complicated with coronary artery disease. *Lipids Health Dis*. 2017;16(1):227.
38. Krysiak R, Gilowski W, Okopien B. The Effect of Metformin and Metformin-Testosterone Combination on Cardiometabolic Risk Factors in Men with Late-onset Hypogonadism and Impaired Glucose Tolerance. *Exp Clin Endocrinol Diabetes*. 2015;123(10):608-13.
39. Everett BM, Donath MY, Pradhan AD, Thuren T, Pais P, Nicolau JC, et al. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. *J Am Coll Cardiol*. 2018;71(21):2392-401.
40. Liang WW. Seasonal changes in preprandial glucose, A1C, and blood pressure in diabetic patients. *Diabetes Care*. 2007;30(10):2501-2.
41. Gikas A, Sotiropoulos A, Pastromas V, Papazafiropoulou A, Apostolou O, Pappas S. Seasonal variation in fasting glucose and HbA1c in patients with type 2 diabetes. *Prim Care Diabetes*. 2009;3(2):111-4.

Tables

Table 1. Baseline characteristics across different trajectories of hs-CRP among 6,349 Chinese adults

Variables	Low-stable	Moderate-increased	Moderate-fluctuated	High-decreased
n	5,174	208	679	288
Age, y	46.3±12.1	48.0±12.2	48.3±9.4	47.0±12.8
Sex, women, %	36.0	30.3	33.1	30.2
BMI, kg/m ²	23.9±3.0	25.9±3.5	23.7±2.7	25.6±3.2
SBP, mmHg	122±16.2	127±15.9	123±12.9	126±16.6
DBP, mmHg	75.9±11.0	80.0±11.8	72.7±9.9	77.2±11.4
FBG, mmol/L	5.1±0.5	5.2±0.6	5.3±0.5	5.2±0.4
HbA1c, %	5.4±0.4	5.5±0.4	5.3±0.3	5.4±0.4
TC, mmol/L	5.0±0.9	5.1±0.9	5.1±0.7	5.0±0.9
TG, mmol/L	1.6±1.3	1.8±1.2	1.4±0.8	1.8±1.1
HDL-C, mmol/L	1.4±0.4	1.2±0.3	1.3±0.3	1.2±0.3
LDL-C, mmol/L	3.0±0.8	3.2±0.8	3.2±0.6	3.1±0.8
eGFR, ml/min/1.73m ²	113±25.1	109±24.2	133±32.5	117±27.3
WBC, 10 ⁹ /L	6.1±1.5	6.9±1.6	6.2±1.6	7.1±1.8
Hs-CRP, mg/L*	0.6 (0.01, 9.9)	2.42 (0.1, 9.4)	0.83 (0.17, 9.9)	3.47 (0.46, 9.95)

Note:

1. **Abbreviation:** hs-CRP, high sensitivity C-reactive protein; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FBG, fasting blood glucose; HbA1c, glycated hemoglobin A1c; TC, total cholesterol; TG, triglyceride; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; eGFR, estimating glomerular filtration rate; WBC, white blood cell.

2. *, abnormal distribution. The data was shown as medium plus full range.

Table 2. Adjusted hazards ratios and 95% confidence intervals for risks of incident diabetes (2016-2018) across different trajectories of hs-CRP during 2013 and 2015 among 6,349 Chinese adults

Model	Different change patterns of high sensitivity C-reactive protein			
	Low-stable	Moderate-increased	Moderate-fluctuated	High-decreased
n	5,174	208	679	288
Case #	168	16	32	19
Age- and sex-adjusted	1 (ref)	2.18 (1.31, 3.64)	1.40 (0.96, 2.05)	1.94 (1.21, 3.12)
Multivariate-adjusted *	1 (ref)	1.71 (1.02, 2.87)	1.44 (0.95, 2.17)	1.37 (0.84, 2.22)
Further adjustment for 2013 hs-CRP*	1 (ref)	1.77 (0.99, 3.17)	1.46 (0.95, 2.24)	1.43 (0.8, 2.54)

Abbreviation: hs-CRP, high sensitivity C-reactive protein.

* Adjusted for age, sex, baseline BMI (kg/m²), systolic blood pressure (mmHg), diastolic blood pressure (mmHg), total cholesterol (mmol/L), triglyceride (mmol/L), low-density-lipoprotein cholesterol (mmol/L), high-density-lipoprotein cholesterol (mmol/L), eGFR (ml/min/1.73m²), fasting blood glucose (mmol/L), and glycated hemoglobin A1c (%).

Table 3. The adjusted hazard ratios and 95% confidence interval for incident diabetes across different hs-CRP groups among 6,349 Chinese adults

Variables	Model	Low-risk	Intermediate-risk	High-risk	Each SD	P trend
		(<1 mg/L)	(1-2.9 mg/L)	(≥3 mg/L)		
Baseline hs-CRP concentration*	n	4,243	1,663	443	--	--
	Case #	157	105	40	--	--
	Model	1 (ref)	1.22 (0.94, 1.58)	1.67 (1.17, 2.39)	1.11 (1.01, 1.22)	0.005
Concentration of hs-CRP in 2015**	n	4,174	1,787	388	--	--
	Case #	111	95	29	--	--
	Model	1 (ref)	1.44 (1.08, 1.9)	1.94 (1.28, 2.94)	1.19 (1.08, 1.30)	0.001
Cumulative average of hs-CRP concentration**	n	5,197	995	157	--	--
	Case #	171	52	12	--	--
	Model	1 (ref)	1.4 (1.001, 1.94)	1.87 (1.03, 3.39)	1.24 (1.04, 1.47)	0.008

Note:

1. **Abbreviation:** hs-CRP, high-sensitivity C-reactive protein.

2. *, based on five years of follow up (2014-2018)

3. **, based on three years of follow-up (2016-2018).

4. Adjusting for age (y) and sex, baseline BMI (kg/m²), systolic blood pressure (mmHg), diastolic blood pressure (mmHg), total cholesterol (mmol/L), triglyceride (mmol/L), low-density-lipoprotein cholesterol (mmol/L), high-density-lipoprotein cholesterol (mmol/L), eGFR

Figures




Figure 1

The trajectory of high sensitivity C-reactive protein in 6,349 Chinese adults. Hs-CRP level during 2013-2015 was classified into 3 levels: low (<1.0 mg/L), moderate (1.0–3.0 mg/L), and high (≥ 3.0 mg/L) based on a statement by American Heart Association. We named four hs-CRP trajectories during 2013-2015 as following: “low-stable” (hs-CRP concentration was low in 2013 and maintained at low concentration in 2014 and 2015), “moderate-fluctuated” (hs-CRP concentration was moderate in 2013, then increased to high concentration in 2014, and decreased to low concentration in 2015), “high-decreased” (hs-CRP concentration was high in 2013 but decreased to moderate concentration in 2014 and 2015), and “moderate-increased (hs-CRP concentration was moderate in 2013 and increased to high concentration in 2014 and 2015)”.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [supplement1.docx](#)